Background: In hepatitis B early antigen (HBeAg)-negative patients, response predictors to current treatment regimens are not well known. Hepatocyte cell cycle may influence hepatitis B virus (HBV ...

Inside the hepatocytes, HBV produces a surplus of viral antigens, including hepatitis B e antigen (HBeAg) and hepatitis B s antigen (HBsAg), which is HBV’s envelope protein. In addition to the ...

丁型肝炎病毒（hepatitis D virus，HDV）感染可导致严重形式的慢性病毒性肝炎，但其对乙型肝炎病毒（hepatitis B virus，HBV）肝硬化患者发生肝细胞癌 ...

a satellite virusoid employing HBV envelope proteins for the entry into hepatocytes. To date, no effective therapy for HDV infection exists. Thus, entry inhibition may represent the first ...

The following is a summary of “Cobalt chloride-mimicked hepatocyte cell hypoxia induces TREX1 leading to Hepatitis B virus ...

At least one-third of the world's population has been infected with the hepatitis B virus (HBV), and 400 million people are chronic carriers. In most populations, chronic HBV infection is the ...

2 SCG101 is designed to target a specific HBV peptide presented on infected cells, as well as hepatocytes with HBV DNA integration. By triggering both cytolytic and non-cytolytic mechanisms ...